Search
Search Results
-
Magnetic Resonance Imaging-Negative Cerebral Amyloid Angiopathy: Cerebrospinal Fluid Amyloid-β42 over Amyloid Positron Emission Tomography
BackgroundCerebral amyloid angiopathy (CAA) pathology is becoming increasingly important in Alzheimer’s disease (AD) because of its potential link to...
-
Characteristics of discordance between amyloid positron emission tomography and plasma amyloid-β 42/40 positivity
Various plasma biomarkers for amyloid-β (Aβ) have shown high predictability of amyloid PET positivity. However, the characteristics of discordance...
-
Amyloid-PET/CT – Überblick und Fallbeispiele
Amyloid positron emission tomography/computed tomography (PET/CT) is a helpful aid in imaging pathological cerebral amyloid deposits and is a proven...
-
Plasma Oligomer β-Amyloid and White Matter Microstructural Integrity in Cognitively Normal Older Adults According to Cerebral Amyloid Deposition
BackgroundMultimer detection system-oligomeric amyloid-β (MDS-OAβ) measure plasma OAβ level, which is associated with earlier Alzheimer’s disease...
-
Anti-amyloid Antibody Therapies for Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common cause of dementia, which is characterized by a progressive neurodegenerative disorder that is extremely...
-
Update on Amyloid Polyneuropathy and Treatment
Purpose of ReviewThe purpose of this review is to summarize currently available and developing diagnostic and treatment options for hereditary...
-
Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer’s disease with APPdup and Down syndrome
Alzheimer’s disease (AD) is characterized by extracellular amyloid plaques containing amyloid-β (Aβ) peptides, intraneuronal neurofibrillary tangles,...
-
Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy
Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is an underrecognized cause of heart failure due to misfolded wild-type transthyretin...
-
Prediction of amyloid PET positivity via machine learning algorithms trained with EDTA-based blood amyloid-β oligomerization data
BackgroundThe tendency of amyloid-β to form oligomers in the blood as measured with Multimer Detection System-Oligomeric Amyloid-β (MDS-OAβ) is a...
-
Clinical Performance Evaluation of an Artificial Intelligence-Powered Amyloid Brain PET Quantification Method
PurposeThis study assesses the clinical performance of BTXBrain-Amyloid, an artificial intelligence-powered software for quantifying amyloid uptake...
-
Value of Knowing: Health-Related Behavior Changes following Amyloid PET Results Disclosure in Mild Cognitive Impairment
BackgroundGrowing evidence supports the clinical utility of amyloid PET, however, whether patients at risk for dementia use knowledge of their brain...
-
Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study
Core Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers have shown incomplete agreement with amyloid-positron emission tomography (PET)....
-
Tumefactive cerebral amyloid angiopathy – related inflammation
IntroductionCerebral amyloid angiopathy–related inflammation (CAA-ri) derives from inflammatory response to β-amyloid (Aβ) protein deposition within...
-
Deep-learning prediction of amyloid deposition from early-phase amyloid positron emission tomography imaging
ObjectiveWhile the use of biomarkers for the detection of early and preclinical Alzheimer's Disease has become essential, the need to wait for over...
-
Clinical characteristics of cerebral amyloid angiopathy and risk factors of cerebral amyloid angiopathy related intracerebral hemorrhage
ObjectivesThere is limited understanding of the differences between cerebral amyloid angiopathy (CAA) with and without intracerebral hemorrhage...
-
Inverse correlation between age of onset and myocardial amyloid deposition quantified by 99mTc-PYP scintigraphy in patients with wild-type transthyretin amyloid cardiomyopathy
ObjectiveWild-type transthyretin amyloidosis cardiomyopathy (ATTRwt-CM) is increasingly recognized as a contributing factor to cardiac insufficiency...
-
Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease
Anti-amyloid treatments for early symptomatic Alzheimer disease have recently become clinically available in some countries, which has greatly...
-
Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future
Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer’s disease (AD), and its accumulation has been considered as the...
-
Modeling of factors affecting late gadolinium enhancement kinetics in MRI of cardiac amyloid
BackgroundLate gadolinium enhancement (LGE) is a valuable part of cardiac magnetic resonance imaging (CMR). In particular, inversion-recovery imaging...
-
Associations of CSF BACE1 with amyloid pathology, neurodegeneration, and cognition in Alzheimer’s disease
Β-site amyloid precursor protein (APP) cleaving enzyme (BACE1) is a crucial protease in the production of amyloid-β (Aβ) in Alzheimer’s disease (AD)...
